Locally produced Molnupiravir can cut prices up to 50% visayandailystar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from visayandailystar.com Daily Mail and Mail on Sunday newspapers.
Photo courtesy of NTF Against Covid-19 MANILA - Local pharmaceutical firm Lloyd Laboratories Inc. (LLI) is eyeing a "fill and finish" operation for a new Chinese vaccine against coronavirus disease (Covid-19) that is still undergoing clinical trials. In a virtual media interview Thursday, LLI medical consultant Dr. Antonio Ligsay said the company has partnered with Livzon Biotech's Livzon Mabpharm, Inc. for the phase three clinical trial of the V-01, a code name for the recombinant vaccine against Covid-19. Ligsay said the interim analysis will be concluded by the end of this month. "Hopefully, our results will be good towards the end of the month, and if it's good, then we will apply for EUA (emergency use authorization)," he added. Ligsay said V-01's phases one and two were conducted in China and the third phase was conducted in the Philippines, Indonesia, and Russia with a total of 21,500 respondents. The Philippines has the largest number of subjects
Molnupiravir(Antara) MANILA - As Philippine pharmaceutical firm Lloyd Laboratories Inc. (LLI) aims producing molnupiravir in the country, prices of this coronavirus disease 2019 (Covid-19) drug could go down by 30 to 50 percent. LLI Business Development director Christopher Bamba said retail prices of imported molnupiravir cost around PHP100 to PHP150 per 200-milligram capsule. "For our pricing, we are usually 30 to 50 percent lower and this is our price strategy being a local manufacturer and a generic company," Bamba said in a media interview Thursday. If the local production will push through, prices of this medicine could be reduced to PHP50 to PHP75 per capsule. LLI vice president for technical Dr. Chandra Shekhara Reddy Nagareddy said the company will bring down the price of locally manufactured molnupiravir as it has no obligation to pay any royalty for producing the medicine. In October last year, Merck signed a royalty-free licensing deal for molnupiravir to make the
Lloyd Laboratories Inc., a firm eyeing to start its production of Molnupiravir this month, is also aiming to apply for an emergency use authorization (EUA) by February for a Covid-19 vaccine that is currently under clinical trials. Antonio Ligsay, medical consultant of the company, told the reporters on Thursday that…
The Board of Investments (BoI) has approved the application for registration of a Bulacan-based producer of Molnupiravir, an oral therapy for Covid-19 patients, whose production may commence this month. The agency said Lloyd Laboratories Inc. recently expanded its production facility to produce the said Covid-19 drug, shelling out P24 million…